Results 41 to 50 of about 782 (172)

Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies

MedComm – Oncology, Volume 2, Issue 3, September 2023., 2023
Microtubule‐targeting agents (MTAs) are pivotal in the field of cancer treatment. This study presents a comprehensive review of the seven binding sites and three strategies (stabilization, destabilization, and degradation) utilized by MTAs, along with an overview of their current clinical applications and challenges.
Xingyu Wang, Benoît Gigant, Xi Zheng, Qiang Chen   +3 more
wiley   +1 more source

Acute High Dietary Phosphorus Following Low‐Phosphorus Diet Acclimation Does Not Enhance Intestinal Fractional Phosphorus Absorption in Nephrectomized Male Rats

JBMR Plus, Volume 6, Issue 12, December 2022., 2022
Acute high dietary phosphorus following low‐phosphorus diet acclimation does not enhance intestinal fractional phosphorus absorption in nephrectomized male rats. ABSTRACT Dietary phosphorus restriction and phosphorus binders are commonly prescribed for patients with chronic kidney disease (CKD).
Kendal M Burstad, Dennis P Cladis, Colby J Vorland, Meryl E Wastney, Annabel Biruete, James M Dominguez II, Kalisha D O'Neill, Neal X Chen, Sharon M Moe, Kathleen M Hill Gallant   +9 more
wiley   +1 more source

Molecular mechanisms, physiological roles, and therapeutic implications of ion fluxes in bone cells: Emphasis on the cation‐Cl− cotransporters

Journal of Cellular Physiology, Volume 237, Issue 12, Page 4356-4368, December 2022., 2022
Ion transport systems in the membranes of osteoblasts and osteoclasts play a key role in bone remodeling by coordinating the movement of Ca2+, PO42−, and H+ ions in and out of the osseous matrix. Based on the evidence available, the cation‐Cl− cotransporters could act as unexpectedly important players in this regard.
Alexandre P. Garneau, Samira Slimani, Ludwig Haydock, Thy‐René Nsimba‐Batomene, Florence C.M. Préfontaine, Mathilde M. Lavoie, Laurence E. Tremblay, Marie‐Jeanne Fiola, Fabrice Mac‐Way, Paul Isenring   +9 more
wiley   +1 more source

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer [PDF]

Gynecologic Oncology, 2020
This study investigated the safety and tolerability of lifastuzumab vedotin (DNIB0600A) (LIFA), an antibody-drug conjugate, in patients with recurrent platinum-sensitive ovarian cancer (PSOC).In this open-label, multicenter phase 1b study, LIFA was administered intravenously once every 3 weeks (Q3W) with starting dose 1.2 mg/kg in a 3 + 3 dose ...
Kathleen N. Moore, Michael J. Birrer, Jim Marsters, Yulei Wang, YounJeong Choi, Stephanie Royer‐Joo, Vanessa Lemahieu, K. S. Armstrong, Julie Cordova, Divya Samineni, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke, Erika Hamilton, Joyce F. Liu   +15 more
openalex   +4 more sources

Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease

Journal of Pharmacy & Pharmaceutical Sciences, 2022
Purpose: This narrative review explores the currently published studies that have evaluated tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) patients on hemodialysis.
Tiffany Lin, Akram Al-Makki, Brian Shepler   +2 more
doaj   +1 more source

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters

British Journal of Pharmacology, Volume 178, Issue S1, Page S412-S513, October 2021., 2021
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets ...
Stephen P H Alexander, Eamonn Kelly, Alistair Mathie, John A Peters, Emma L Veale, Jane F Armstrong, Elena Faccenda, Simon D Harding, Adam J Pawson, Christopher Southan, Jamie A Davies, Laura Amarosi, Catriona M. H. Anderson, Philip Mark Beart, Stefan Broer, Paul A. Dawson, Bruno Hagenbuch, James R. Hammond, Jules C Hancox, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Gavin Stewart, David T. Thwaites, Tiziano Verri   +24 more
wiley   +1 more source

Unusual presentation of a five‐month‐old boy with NaPi2a homozygous mutation without hyperphosphaturia: Case report and review of the literature

Clinical Case Reports, Volume 9, Issue 9, September 2021., 2021
Deletions of the NaPi2a gene and mutations in the SLC34A gene should be considered in patients with atypical presentation, without phosphaturia, with mild hypo to normal phosphatemia, and nephrocalcinosis. Abstract Deletions of the NaPi2a gene and mutations in the SLC34A gene should be considered in patients with atypical presentation, without ...
Renata Yakubov, Asaly Ayman, Adi Klein Kremer, An Bael, Machiel van den Akker   +4 more
wiley   +1 more source

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Cancer Medicine, Volume 10, Issue 14, Page 4677-4696, July 2021., 2021
Antibody drug conjugate (ADC) has been under rapid development in recent years, the application of ADC has changed traditional treatment patterns for pan‐cancer patients and has become a great breakthrough for individualized precision treatment. We conducted this review to summarize basic characteristics, clinical progress, and challenges of ADCs to ...
Wen‐Qian Li, Han‐Fei Guo, Ling‐Yu Li, Yong‐Fei Zhang, Jiu‐Wei Cui   +4 more
wiley   +1 more source

Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation

Annals of Oncology, 2019
Abstract Background Searching for specific targets in cancer diagnosis and treatment is one of the most important problems in clinical oncology. We put forward a new concept of the emergence of tumor-specific epitopes of integral membrane proteins by changing their topology under mutations, glycosylation and tumor conditions including low pH and ...
L.F. Minigulova, V. Skripova, A.K. Nurgalieva, N. E. Ionova, D. Reshetnikova, Mikhail Bogdanov, Ramziya Kiyamova   +6 more
openalex   +3 more sources

Highway to Success—Developing Advanced Polymer Therapeutics

Advanced Therapeutics, Volume 4, Issue 5, May 2021., 2021
Polymer therapeutics have the potential to be an important class of next generation medicines. Adapting and applying a successful framework for increased research and development productivity to the design and development of polymer therapeutics should improve their clinical translation.
Marianne B. Ashford, Richard M. England, Nadim Akhtar   +2 more
wiley   +1 more source